By Susanna Moon
Chicago, Feb. 27 - Response Genetics, Inc. said it entered into a purchase agreement with certain affiliated funds of Special Situations Funds to raise $2 million from the private placement of shares.
The company will sell 2 million common shares at $1.00 per share.
Settlement is expected to occur on March 2.
Response Genetics, Inc. is Los Angeles company engaged in the research and development of its clinical diagnostic tests for cancer.
| Issuer: | Response Genetics, Inc.
|
| Issue: | Common stock
|
| Amount: | $2 million
|
| Shares: | 2 million
|
| Price: | $1.00 per share
|
| Warrants: | No
|
| Pricing date: | Feb. 27
|
| Settlement date: | March 2
|
| Stock symbol: | Nasdaq: RGDX
|
| Stock price: | $1.16 at close on Feb. 26
|
| Market capitalization: | $13.67 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
